Insight Investment and Financing Database shows that, last week, there were 17 investment and financing events in the global pharmaceuticals field (As of December 6）：- In terms of drug types, in addition to small molecules and antibodies, the fields that are highly favored by capital also includeCell and Gene Therapy, Conjugated Drugs, Oncolytic Viruses, T Cell Engagersetc.;
- From a regional distribution perspective, the companies that have received financing are stillMainly from the United States, accounting for approximately 47%; Chinese companies' financing accounts for about 17%;
- In China,Wuhan Kaidewei Biotechnology Co., Ltd, Signet Therapeutics, Yafei Biomedical,逸达生技and other companies have completed a new round of financing;
- In terms of the amount, Revolution Medicines, a rising star in RAS inhibitor development, raised the highest funding.Reaching 862.5 Million US Dollars。
Below, the Insight database will introduce some selected highly anticipated financing cases for readers' reference only.
China's New Sharp Financing Yafei Biomedical Completes Over 400 Million YuanB2 RoundFinancingYafei Biomedical, the parent company of Affinity Biosciences, announced the completion ofSDIC CapitalLead InvestmentThe over 400 million yuan B2 round of financing, with other investors including Huachuang Capital, Hongcheng Investment, Guozheng Investment, etc. This round of financing will provide momentum for Yafei Biomedical in the global innovative drug clinical research process, and accelerate the development of its technology platform and drugs.Qinhe Force is committed to research, development, production, commercialization, and external cooperation.Innovative Anti-cancer Drugs. The company has developedMore than 20 innovative candidate drugs, including small molecule conjugate drugs specifically activated by the tumor microenvironmentLigubixCurrently being carried out in ChinaTreatment of Soft Tissue SarcomaPhase II/III Clinical Trials. SIGNET Raises Over 70 Million Yuan in Pre-A Round FinancingSIGNET Announces Over 70 Million Yuan in Pre-A Round Financing and Project Funding. This round of financing will be used to support its first pipeline, SIGX1094.Ⅰ Phase trials, expedite the IND application process for the second pipeline, optimize and upgrade the organoid disease model platform, etc.SIGNET was founded at the end of 2020 and is aCancer Innovative Targeted Drug Development Based on Organoid Disease Models + AICompanySIGX1094 is a potential "first-in-class" targeted drug under research by the company, currently in a multicenter Phase 1 clinical trial for diffuse gastric cancer and other advanced solid tumors. Wuhan Kaidewei Biotechnology Co., Ltd. Completes Nearly 200 Million Yuan in Series B FinancingWuhan Kaidewei Biotechnology Co., Ltd. Announces Completion ofFir Creek Capital Leads the InvestmentThe nearly 200 million yuan B-round financing, with other investors including Wuhan Gaoke, Hongtai Industrial Finance, Hubei Science Investment, Jiuzhou Tong Chuchang Investment, etc. This round of funding will be used for the clinical development and market expansion of its various products in the field of gynecological tumor diagnosis and treatment.Wuhan Kaidewei Biotechnology Co., Ltd was founded by an academician of the Chinese Academy of Engineering.Professor MartinFounded and focused on the entire process of gynecological tumor screening, diagnosis, prevention, and treatment. Currently, the company'sNovel Recombinant Oncolytic Adenovirus ProductHave been approved to enter Phase I clinical trials, and two in vitro diagnostic kits have been approved to enter the innovative medical device review fast track.
Revolution Completes Over $860 Million FinancingRevolution Medicines Announces Completion of Large-Scale Public Offering of Common Stock and Pre-Financing WarrantsTotal revenue was $862.5 million。Revolution Medicines' R&D pipeline includesMultiple RAS (ON) InhibitorsAiming to inhibit various oncogenic mutations of RAS proteins. Among them, the pan-RAS inhibitor RMC-6236, the selective RAS G12C covalent inhibitor RMC-6291, and the selective RAS G12D inhibitor RMC-9805 have all entered clinical stages. Janux Completes $350 Million FinancingJanux Therapeutics Announces Approximately $350 Million Financing to Advance Clinical Development of Internal Pipeline and for General Corporate PurposesJanux is focused on developingTumor-Activated Immunotherapy, currently based on its Tumor-Activated T Cell Engager（TRACTr）And Tumor-Activating Immunomodulators（TRACIr）The platform has developed multiple solid tumor treatment products, with targets including PSMA, EGFR, etc. Nuvig Secures $161 Million in Series B FinancingNuvig Therapeutics Announces $161 Million Series B Financing Co-Led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners. The proceeds will support clinical proof-of-concept studies for NVG-2089 and advance its preclinical pipeline.Nuvig is advancing the use ofChronic InflammationAndAutoimmune DiseasesA novel immunotherapy pipeline. Its leading research candidate, NVG-2089, upregulates the expression of FcgRIIb after binding to the target, leading to the expansion of T regulatory cells and the downregulation of multiple inflammatory pathways. Currently, the product is advancing into Phase II clinical trials for use inChronic Inflammatory Demyelinating Polyneuropathy（CIDP）And other undisclosed indications. Maze Completes $115 Million FinancingMaze Therapeutics Announces $115 Million Series D Financing Co-Led by Frazier Life Sciences and Deep Track Capital, with Additional Investors Including Janus Henderson Investors, Logos Capital, Third Rock Ventures, and Others.Maze is committed to leveraging the power of human genetics to develop novel small-molecule precision medicines for patients, with a focus onKidney, CardiovascularAndRelated Metabolism (Including Obesity)and other fields. This round of financing will support the development of its key projects, MZE829 (oral APOL1 inhibitor) and MZE782 (oral SCL6A19 inhibitor),These two potential therapies for kidney disease are currently in Phase I trials.。 Antag Completes €80 Million Series A FinancingAntag Therapeutics Announces €80 Million Series A Financing Led by Versant Ventures, with Additional Investors Including Novo Holdings, SR One, Dawn Biopharma, and Pictet. The proceeds will support the clinical development of AT-7687 and advance the expansion of the company’s therapeutic pipeline.Antag is committed to discovering and developing new therapies for treating obesity and cardiometabolic diseases through GIP receptor antagonists. Among them,AT-7687 is a novel, once-weekly, glucose-dependent insulinotropic polypeptide receptor (GIPR) subcutaneous injection antagonist.The FDA recently accepted the IND application for this product, with clinical development expected to begin early next year. Foresee Completes $42.1 Million FinancingForesee Pharmaceuticals Announces Completion of Public Offering of 18 Million Common Shares, Raising a Total of TWD 1.368 Billion (Approx. USD 42.1 Million). The proceeds from this financing will be used to advance the clinical trials of the company's multiple pipeline products.Currently, in Foresee's R&D pipeline: the ready-to-use long-acting injectable FP-014 is under development for treatment.Advanced Prostate CancerPhase III clinical trial; MMP-12 inhibitor FP-020 is under development for treatmentAsthma and Inflammatory Bowel DiseasePhase II Clinical Trial; ALDH2 Activator FP-045 is Undergoing TreatmentPulmonary Hypertension and Interstitial Lung DiseaseTheⅡPhase Clinical. KisoJi Completes $41 Million FinancingKisoJi Biotechnology Announces Completion of $41 Million Equity Financing Led by Investissement Quebec and Lumira Ventures, with Additional Investors Including Fonds de solidarite FTQ, adMare BioInnovations, and Remiges Ventures.KisoJi focuses on the discovery and development of innovative antibody therapies.Main Candidate Drug KJ-103 is aPotent naked antibody drug targeting TROP2。This round of financing will be used to advance KJ-103 into clinical trials for the treatment of solid tumors; it will also be utilized to deploy the company’s antibody discovery platform to develop new multispecific therapeutic antibody drugs for cardiometabolic diseases, immunological disorders, and inflammation. Senti Bio Completes $37.6 Million FinancingSenti Bio Secures Approximately $37.6 Million in Financing. This Round Was Led by Celadon Partners, with Other Investors Including New Enterprise Associates.（NEA）, Leaps by Bayer, Nantahala Capital, etc.
Senti Bio is committed to patients suffering from incurable diseasesDeveloping the Next Generation of Cell and Gene TherapiesThe company is leveraging a synthetic biology platform known as "gene circuits" to create therapies with greater precision and control. SENTI-202 is a product developed by Senti Bio.A Logic-Gated Off-the-Shelf CAR-NK Therapy, and has already achieved positive results in early trials targeting hematologic malignancies.
Jupiter Listed on NASDAQ
Jupiter Neurosciences Announces NASDAQ Listing in the United States, Expecting Total Gross Proceeds of $11 Million from the Offering. The proceeds will be used to advance its lead product candidate.Phase II Clinical Trial of JOTROL in Patients with Parkinson's Disease, a strategic service agreement to accelerate business activities in Southeast Asia, as well as support for R&D activities related to new products, etc.
Jupiter CompanyFocus on Central Nervous System Diseases and Rare DiseasesThe product pipeline covers indications such as Alzheimer's disease, Parkinson's disease, Mucopolysaccharidosis Type I, Friedreich's ataxia, and MELAS syndrome. Among them, JOTROLIt is an enhanced oral resveratrol formulation that has previously completed Phase I safety and tolerability trials.
In addition to the above cases, some other companies also received financing last week. Due to space limitations, they will not be introduced one by one here. For more financing information from last week, please click.「Read the Original Text」Go to Insight Database "New Drug Investment and Financing"ModelBlock View.
Cover Source:ZCOOL Hello PlusDisclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.PR Article Coordination: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
